Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease - Test2 - elhamkhani - TriplyDB

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease

http://www.wikidata.org/entity/Q28080515

about

A monoclonal natural human IgM protects axons in the absence of remyelination Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Remyelination: A Potential Therapeutic Strategy for Alzheimer's Disease?Nogo-A Antibodies for Progressive Multiple Sclerosis.A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.

P2860

Q36851038-631AA951-095E-465E-859F-924B5F1A235D Q37019872-BB0DE8D1-BA86-45AF-956E-18D714E8687C Q38814687-051009D4-D509-439D-8FD3-4759D723DB27 Q39010894-FE12ED92-80CD-4A39-B28E-031D175CBA6A Q49169217-A783D8DF-112E-4ADD-A80E-8683072C0F1B

P2860

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease

http://www.wikidata.org/entity/Q28080515

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@ast

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@en

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@nl

type

label

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@ast

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@en

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@nl

prefLabel

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@ast

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@en

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@nl

P1433

Q28080515-8EE309D3-395C-43E9-8D18-567065832D6B

P1476

Q28080515-17FC5F70-E256-4ACD-956B-861A28DA99D2

P2093

Q28080515-8B10F28E-2BC2-4642-A8E8-174B8CDF710D

Q28080515-A4CFCBA8-6255-4088-BBDA-F95EB55AAFA2

P275

Q28080515-4A37FC1A-83AD-4087-B47A-0ED3B7F4D85D

P2860

Q28080515-05807A7B-28E4-47EF-B54A-875B17BD472F

Q28080515-0F99E1CA-4745-4FE6-8290-A0B36CA876F9

Q28080515-0FCBDF08-A6C8-46F4-96D1-3914AB77A465

Q28080515-122D842B-5FEB-43A7-A585-719B407EC224

Q28080515-1412D768-BB7A-4771-B09B-9655A805656E

Q28080515-20A13020-D604-4D6A-9456-8FB663A15081

Q28080515-3594DCF6-8B3E-41F7-9307-474DF626F8CA

Q28080515-3617E247-A6A4-48A2-BD7C-52839C9F9834

Q28080515-4326417B-4A2A-4E0F-BE6B-8C364730A4A3

Q28080515-43DA9474-4AC9-496C-A7D7-9E217F189DAB

P2888

Q28080515-BFB6E796-63C2-4B51-AF76-E36527E41AFD

P304

Q28080515-FE43D08E-AEB1-4075-90FA-7057828F9491

P31

Q28080515-E92C3475-71B4-4497-AB09-B3CD0F72B1B2

P3181

Q28080515-5B9FB85C-168E-4231-82A4-95D3B8D2CE91

P356

Q28080515-0F125B8F-72F6-41C8-A1F1-9948808F3DF9

P407

Q28080515-8E8735D5-77E0-44A4-8E49-24013E57C164

P433

Q28080515-00AFD6D7-AD4E-413B-98F8-BFF4EC54A476

P478

Q28080515-5B8CA831-FB31-4B33-BEBD-EA91AB3FE546

P50

Q28080515-360FEA3B-03A2-4288-9DCD-08955759D7EE

Q28080515-648FC6A8-2218-41F5-930A-18EA3CD04523

Q28080515-B0C53240-DF81-4DE2-9F32-E4D36B25801F

P5008

Q28080515-B791396B-5ACE-45C8-9730-516EB6CC33A7

P577

Q28080515-3110714F-2347-4FE3-A59C-B80ED82C2BAC

P5875

Q28080515-00BE86D5-7196-490D-B67B-A28C4C68ED49

P6179

Q28080515-D3FEE97E-8D48-46E3-AE8B-8DC0AC43FF03

P698

Q28080515-409E0778-86B9-4808-A80E-EF9BB1871ABE

P921

Q28080515-3975D006-38D3-4778-B6CC-DD5400634FFA

Q28080515-4085021E-29D1-42F8-B6A7-192DC01C5E10

Q28080515-447804B0-86C2-41C8-BFFA-252B961EA0BD

Q28080515-AF355372-A329-401E-8BE7-0A3DFB479E10

Q28080515-EC1778E3-1CEB-45D6-B752-5D4DD15A7924

Q28080515-F855AA20-7290-4ADD-A4FF-7CB9FB7A6493

Q28080515-FA31FA5C-302D-42EC-B038-675A91A1C37D

P932

Q28080515-6E7400B4-00AF-443B-B1DF-E065844E62DC

P3181

P356

S12035-015-9436-3

P1433

Molecular Neurobiology

P1476

Antibody-Mediated Oligodendroc ...... gressive Demyelinating Disease

@en

P2093

Aleksandar Denic

http://www.w3.org/2001/XMLSchema#string

Arthur E Warrington

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Epidemiologic evidence for multiple sclerosis as an infection

LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.

The molecular pathogenesis of Pelizaeus-Merzbacher disease

ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury

Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination

LINGO-1 negatively regulates myelination by oligodendrocytes

A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination

Axonal transection in the lesions of multiple sclerosis

Multiple sclerosis

A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination.

P2888

s12035-015-9436-3

P304

5217-5228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2014172

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S12035-015-9436-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Moses Rodriguez

Jens O Watzlawik

P5008

P577

2015-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282248350

http://www.w3.org/2001/XMLSchema#string

P6179

1040998722

http://www.w3.org/2001/XMLSchema#string

P698

26409478

http://www.w3.org/2001/XMLSchema#string

P921

demyelinating disease

oligodendrocyte

P932

5012151

http://www.w3.org/2001/XMLSchema#string